Genteric's Gene Pill Approach Researchers from Genteric have invented a new method of gene delivery that employs the patient's own gastrointestinal tract to produce and secrete therapeutic proteins into the bloodstream. In the therapy's mature stage, the patient could swallow a pill containing engineered DNA that encodes the needed protein. A key feature of these intestinal cells is that, like skin cells, they are constantly replaced. Thus, the gene is expelled with the dying cells on a regular basis - about every other day. This natural feature enhances safety and efficient dose control.
Oral administration allows different dose levels to be given according to patient needs.
The body replaces cells at this site quickly, which gives greater control of gene delivery and helps to avoid long-term side effects. During these stages, researchers will address challenges in oral delivery, such as methods to adjust the amount of insulin expressed and durability of coating materials used to protect the DNA as it is delivered to cells in the intestinal tract. The company has pioneered new methods of gene-based drug delivery that employ the secretory organs of the patient's gastrointestinal system to produce and release therapeutic proteins into the bloodstream. Along with Michael H. Nantz, Ph.D., professor of chemistry at UC Davis, they founded the company three years ago. Dr. Rothman presently serves as Chair of the Company's Scientific Advisory Board.